Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers

A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

Participants needed: 60
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Korea United Pharm. Inc.Updated: Jul 27, 2026Locations: 1
Eligibility criteria

Healthy adult volunteers aged 19 years or older at the time of screening. [+6]

Current or past history of clinically significant liver, kidney, neurological, p... [+24]

Status: Recruiting

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

Participants needed: 36
Trial details
Phase: Phase 1Age: 19-54Biological sex: AllType: InterventionalSponsor: Korea United Pharm. Inc.Updated: Jul 6, 2026Locations: 1
Eligibility criteria

Subjects aged 19 years or older and less than 55 years at the screening visit. [+6]

Subjects with current or past history of clinically significant diseases involvi... [+24]

Status: Not yet recruiting

A Study to Evaluate the Safety and Pharmacokinetics of UI087 Compared to Coadministration of UIC202506, UIC202507 and UIC202508 in Healthy Adult Volunteers Under Fasting Conditions

This study was an open-label, randomized, single-dose, 2-sequence, 2-period, crossover study to evaluate the safety and pharmacokinetics of UI087 compared to coadministration of UIC202506, UIC202507 and UIC202508 in healthy adult volunteers under fasting conditions

Participants needed: 44
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Korea United Pharm. Inc.Updated: Apr 23, 2026Locations: 1
Eligibility criteria

Subjects aged 19 years or older at the screening visit [+7]

Subjects with clinically significant diseases or a history of diseases involving... [+21]

Status: Recruiting

A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.

Participants needed: 50
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Korea United Pharm. Inc.Updated: Sep 9, 2025Locations: 1
Eligibility criteria

Subjects aged 19 years or older at the time of screening. [+5]

Subjects with clinically significant diseases or a history of conditions involvi... [+9]